KR940009201A - V족 주그룹의 원자량이 큰 원소를 함유하는 인지질 유도체 - Google Patents
V족 주그룹의 원자량이 큰 원소를 함유하는 인지질 유도체 Download PDFInfo
- Publication number
- KR940009201A KR940009201A KR1019930020113A KR930020113A KR940009201A KR 940009201 A KR940009201 A KR 940009201A KR 1019930020113 A KR1019930020113 A KR 1019930020113A KR 930020113 A KR930020113 A KR 930020113A KR 940009201 A KR940009201 A KR 940009201A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- diseases
- group
- preparing
- Prior art date
Links
- 150000003904 phospholipids Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 4
- 229910052787 antimony Inorganic materials 0.000 claims abstract 2
- 229910052785 arsenic Inorganic materials 0.000 claims abstract 2
- 229910052797 bismuth Inorganic materials 0.000 claims abstract 2
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims 3
- 208000014951 hematologic disease Diseases 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 239000003456 ion exchange resin Substances 0.000 claims 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000012043 crude product Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 238000006460 hydrolysis reaction Methods 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
- C07F9/5407—Acyclic saturated phosphonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/66—Arsenic compounds
- C07F9/70—Organo-arsenic compounds
- C07F9/72—Aliphatic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cephalosporin Compounds (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
Abstract
본 발명은 V족 주그룹의 원자량이 큰 원소(예：P, As, Sb, Bi)를 함유하는 인지질 유도체, 이의 제조방법 및 인지질 유도체로부터 제조할 수 있는 항신생물질 항균성 활성 약제에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (9)
- 일반식(I)의 화합물.상기식에서, R5는 1개 내지 3개의 이중결합 또는 삼중결합을 함유할 수 있는 탄소수 10 내지 24의 직쇄 또는 측쇄 알킬 라디칼이고, A는 단일결합이거나, 일반식(II) 내지 (IV)의 그룹 중의 하나이고,(여기서, R7은 탄소수 1 내지 4의 직쇄 알킬 그룹이며, (II) 내지 (IV)의 그룹은 산소원자가 일반식(I)의 화합물의 인원자에 결합되도록 배향된다)X는, A가 단일결합인 경우, 산소원자, 황원자 또는 NH이고, A가 일반식(II) 내지 (IV)의 그룹인 경우, 산소원자 또는 황원자이고, A1은 탄소수 2 내지 10의 직쇄 또는 측쇄 알킬 라디칼이고, R6은 (+)YR8R9R10(여기서, R8내지 R10은 동일하거나 상이한 탄소수 1 내지 6의 직쇄, 측쇄 또는 사이클릭 알킬라디칼이거나, 수소이다)이고, Y는 P, As, Sb 또는 Bi이거나, 일반식(VII)의 그룹이다.(여기서, n은 0 또는 1이고, W는 CH2, O, NH 또는 S이고, W가 CH2가 아닌 경우, n은 1이다)
- 옥시염화인을 공지된 방법으로 용매 속에서 또는 용매의 부재하에 n-알칸올과 반응시켜 수득한 생성물을 분리 및 정제없이 일반식(VIII)의 화합물과 추가로 반응시킨 후 가수분해시킴을 특징으로 하여, 제1항에 따른 일반식(I)의 화합물을 제조하는 방법.상기식에서, A, A1, A5, R6및 R7은 제1항에서 정의한 바와 같다.
- 일반식(IX)의 화합물을 일반식(X) 또는 (XI)의 화합물과 반응시킴을 특징으로 하여, 제1항에 따른 일반식(I)의 화합물을 제조하는 방법.상기식에서, R1, X, A, A1, Y, R5, R6, R7, R8, W, m 및 n은 제1항에 정의한 바와같다.
- 일반식(XIII)의 화합물을 하기 일반식의 인산수소와 반응시킴을 특징으로 하는 제1항에 따른 일반식(I)의 화합물을 제조하는 방법.상기식에서, R1, X, Z, A1, R5, R6및 Z는 제1항에서 정의한 바와 같다.
- 일반식(XII)의 화합물을 일반식(X) 또는 (XI)의 화합물과 반응시킴을 특징으로 하여, 제1항에 따른 일반식(I)의 화합물을 제조하는 방법.상기식에서, Z1은 염소, 브롬, 메실레이트, 토실레이트 또는 요오드이고, R1, X, A, A1, R6, R7, R8, W 및 n은 제1항에서 정의한 바와 같다.
- 조생성물을 혼합상 이온교환수지와, 또는 산 및/또는 염기 이온교환수지를 동시에 또는 연속적으로 사용하여 처리함을 특징으로 하여, 제2항 내지 제5항에서 수득할 수 있는 화합물을 정제하는 방법.
- 종양 및 원충성 질환, 피부 및 자기면역질환, 바이러스성 질환, 박테리아성 감염 및 혈액 질환 뿐만아니라 골다공증 치료용 약제를 제조하기 위한, 제1항에서 따른 화합물의 용도.
- 일반식(I)의 화합물 0.1내지 600mg을 통상적인 충전제, 희석제 및 보조물질을 사용하여 약제로 가공함을 특징으로 하여, 종양 및 원충성 질환, 피부 및 자기면역질환, 바이러스성 질환, 박테리아성 감염 및 혈액 질환 치료용 약제를 제조하는 방법.
- 일반식(I)의 화합물 0.1내지 600mg을 함유함을 특징으로 하는 종양 및 원충성 질환, 피부 및 자기면역질환, 바이러스성 질환, 박테리아성 감염 및 혈액 질환 뿐만 아니라 골다공증 치료용 약제.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4233044.0 | 1992-10-01 | ||
| DE4233044A DE4233044A1 (de) | 1992-10-01 | 1992-10-01 | Phospholipidderivate, die höhere Elemente der V. Hauptgruppe enthalten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR940009201A true KR940009201A (ko) | 1994-05-20 |
| KR100331367B1 KR100331367B1 (ko) | 2002-11-13 |
Family
ID=6469408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019930020113A KR100331367B1 (ko) | 1992-10-01 | 1993-09-28 | V족주그룹의원자량이큰원소를함유하는인지질유도체,이의제조방법및정제방법,및이를함유하는약제 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US5449798A (ko) |
| EP (1) | EP0594999B1 (ko) |
| JP (1) | JP3688304B2 (ko) |
| KR (1) | KR100331367B1 (ko) |
| CN (1) | CN1055697C (ko) |
| AT (1) | ATE174030T1 (ko) |
| AU (1) | AU661795B2 (ko) |
| BR (1) | BR9303990A (ko) |
| CA (1) | CA2107439C (ko) |
| DE (2) | DE4233044A1 (ko) |
| DK (1) | DK0594999T3 (ko) |
| EG (1) | EG20258A (ko) |
| ES (1) | ES2125935T3 (ko) |
| FI (1) | FI111261B (ko) |
| GR (1) | GR3029423T3 (ko) |
| HU (1) | HU220593B1 (ko) |
| IL (1) | IL107141A (ko) |
| MX (1) | MX9306076A (ko) |
| NO (1) | NO305911B1 (ko) |
| PH (1) | PH29951A (ko) |
| RU (1) | RU2126413C1 (ko) |
| UA (1) | UA39163C2 (ko) |
| ZA (1) | ZA937282B (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP026997A0 (en) | 1997-11-07 | 1997-12-04 | Resmed Limited | Administration of cpap treatment pressure in presence of apnea |
| US20060116354A1 (en) * | 2003-01-09 | 2006-06-01 | Perkins Walter R | Antineoplastic ether lipid compounds with modifications at the sn-3 carbon |
| JP5232009B2 (ja) | 2005-12-19 | 2013-07-10 | エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 低減された細胞毒性を有するアルキルリン脂質誘導体並びにそれらの使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4177216A (en) * | 1974-06-21 | 1979-12-04 | The Dow Chemical Company | Novel tributyl (2,5-dihydroxyphenyl)phosphonium hydroxide inner salts |
| US4177716A (en) * | 1978-02-21 | 1979-12-11 | Gerald J. Bowe | Automatic energy saver and fire damper for exhaust systems |
| JPS5984824A (ja) * | 1982-11-08 | 1984-05-16 | Takeda Chem Ind Ltd | 抗腫瘍剤 |
| EP0916343A1 (de) * | 1989-09-27 | 1999-05-19 | ASTA Medica Aktiengesellschaft | Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen |
| DE3942933A1 (de) * | 1989-12-23 | 1991-06-27 | Boehringer Mannheim Gmbh | Verwendung von alkylphospholipiden als antivirale arzneimittel und neue phospholipid-derivate |
| DE4111105A1 (de) * | 1991-04-05 | 1992-10-08 | Max Planck Gesellschaft | Neue erucyl-, brassidyl- und nervonylderivate |
-
1992
- 1992-10-01 DE DE4233044A patent/DE4233044A1/de not_active Withdrawn
-
1993
- 1993-06-25 EG EG92893A patent/EG20258A/xx active
- 1993-09-13 EP EP93114671A patent/EP0594999B1/de not_active Expired - Lifetime
- 1993-09-13 AT AT93114671T patent/ATE174030T1/de not_active IP Right Cessation
- 1993-09-13 ES ES93114671T patent/ES2125935T3/es not_active Expired - Lifetime
- 1993-09-13 DK DK93114671T patent/DK0594999T3/da active
- 1993-09-13 DE DE59309182T patent/DE59309182D1/de not_active Expired - Fee Related
- 1993-09-22 US US08/124,492 patent/US5449798A/en not_active Expired - Lifetime
- 1993-09-28 CN CN93118218A patent/CN1055697C/zh not_active Expired - Fee Related
- 1993-09-28 IL IL107141A patent/IL107141A/en not_active IP Right Cessation
- 1993-09-28 KR KR1019930020113A patent/KR100331367B1/ko not_active IP Right Cessation
- 1993-09-30 RU RU93054776A patent/RU2126413C1/ru not_active IP Right Cessation
- 1993-09-30 FI FI934297A patent/FI111261B/fi active
- 1993-09-30 BR BR9303990A patent/BR9303990A/pt not_active Application Discontinuation
- 1993-09-30 PH PH46986A patent/PH29951A/en unknown
- 1993-09-30 CA CA002107439A patent/CA2107439C/en not_active Expired - Fee Related
- 1993-09-30 AU AU48747/93A patent/AU661795B2/en not_active Ceased
- 1993-09-30 NO NO933505A patent/NO305911B1/no unknown
- 1993-09-30 UA UA93002238A patent/UA39163C2/uk unknown
- 1993-09-30 HU HU9302772A patent/HU220593B1/hu not_active IP Right Cessation
- 1993-09-30 MX MX9306076A patent/MX9306076A/es unknown
- 1993-09-30 ZA ZA937282A patent/ZA937282B/xx unknown
- 1993-10-01 JP JP24683293A patent/JP3688304B2/ja not_active Expired - Fee Related
-
1995
- 1995-04-14 US US08/421,920 patent/US5637577A/en not_active Expired - Fee Related
-
1999
- 1999-02-17 GR GR990400506T patent/GR3029423T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2337857A1 (en) | Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-[[(4-aminophenyl) sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate | |
| DE3853579T2 (de) | Tri-azamakrozyklen und deren metall komplexe. | |
| EP0273315B1 (en) | Ammine-n-heterocyclic-platinum complexes and antitumor agents | |
| JPH0597878A (ja) | エルシル−、ブラシジル−およびネルボニル誘導体、その製造方法、それを含有する腫瘍および原虫によるおよび菌類による疾患に対抗するための医薬および自己免疫疾患および骨髄障害の治療のための医薬およびその医薬の製造方法 | |
| GB2077720A (en) | Organic complex of platinum | |
| FR2374334A1 (fr) | Nouveaux nucleosides utiles comme medicaments et procede pour leur preparation | |
| KR900003513B1 (ko) | 유기 백금 착물 및 이를 사용한 종양 치료방법 | |
| EP0282672B1 (en) | Novel platinum complexes | |
| GB1565794A (en) | Neocarzinostatin derivatives and a process for producing the same | |
| NZ212295A (en) | Pharmaceutical compositions containing phosphino-hydrocarbon-gold, silver, or copper complexes; and certain of the complexes | |
| FR2572399B1 (fr) | Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant | |
| FR2367750A1 (fr) | Acid | |
| KR940009201A (ko) | V족 주그룹의 원자량이 큰 원소를 함유하는 인지질 유도체 | |
| EP0127884B1 (en) | Novel glycolic acid type platinum complexes | |
| EP0210753A3 (en) | Anti-tumor medicament | |
| EP0027597B1 (en) | Mono(2-ammonium-2-hydroxymethyl-1,3-propanediol)(2r-cis)-(3-methyloxiranyl)phosphonate, its preparation and pharmaceutical compositions containing it | |
| JPS6140265A (ja) | がん治療用白金挿入組成物 | |
| JPH04502311A (ja) | 有機金属化合物、その調整方法及びそれを含む薬剤化合物 | |
| EP0214862B1 (en) | Anti-tumour platinum complexes, their preparation and their use | |
| US3833729A (en) | Novel pyrazolidone derivatives in pharmaceutical compositions and methods | |
| ATE1150T1 (de) | Anthracyclinglycosiden, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen. | |
| DE3323316A1 (de) | Bis-(2,2-dimethyl-1-aziridinyl)-phosphinsaeure -amide, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| JPS6110594A (ja) | ホスフイノ‐炭化水素‐金、銀または銅錯体含有腫瘍細胞成長抑制医薬組成物 | |
| JPS61249993A (ja) | 新規有機白金錯体及びその製法 | |
| US3787389A (en) | Pyrazolidone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| N231 | Notification of change of applicant | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20070227 Year of fee payment: 6 |
|
| LAPS | Lapse due to unpaid annual fee |